Metfogamma 500 (Metformin Hydrochloride)

Metfogamma (metformin hydrochloride) is employed in the management of disorders that involve insulin resistance and elevated blood glucose.

• Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity.
• Prediabetes (impaired fasting glucose): helps delay progression to overt type 2 diabetes.
• Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

• Metformin hydrochloride acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which decreases hepatic gluconeogenesis. It also increases peripheral glucose uptake by activating AMP‑activated protein kinase (AMPK), thereby improving insulin sensitivity in muscle and adipose tissue and lowering circulating glucose concentrations.

Metfogamma may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools.
• Abdominal discomfort: cramping or pain.
• Metallic taste: transient alteration of taste perception.
• Weight loss: modest reduction in body weight.
• Loss of appetite: decreased desire to eat.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic disturbance.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic dysfunction: elevated liver enzymes.
• Pancreatitis: inflammation of the pancreas.
• Anemia: reduction in red blood cell count.
• Hypoglycaemia: low blood sugar, usually when combined with other glucose‑lowering agents.

When prescribing Metfogamma, clinicians should consider several safety measures to minimise risk.

• Renal function monitoring: assess creatinine clearance before initiation and periodically thereafter.
• Hepatic function monitoring: evaluate liver enzymes at baseline and during therapy.
• Contraindication in severe heart failure: avoid use in patients with unstable or acute heart failure.
• Use with caution in the elderly: dose adjustments may be required due to reduced renal clearance.
• Pregnancy and lactation: safety category unknown; weigh potential benefits against risks.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metfogamma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging.
• Cimetidine: may raise metformin plasma concentrations.
• Alcohol: potentiates risk of lactic acidosis.
• Diuretics that impair renal function: can reduce metformin clearance.
• Certain antiretrovirals (e.g., didanosine): may increase toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• NSAIDs: can affect renal perfusion, requiring dose review.
• Sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed.
• Digoxin: monitor for signs of toxicity.